Upload
the-monterey-county-herald
View
217
Download
0
Embed Size (px)
Citation preview
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
1/23
Supplementary Appendix
This appendix has been provided by the authors to give readers additional information about their work.
Supplement to: Mitchell JM. Urologists use of intensity-modulated radiation therapy for prostate cancer. N Engl
J Med 2013;369:1629-37. DOI: 10.1056/NEJMsa1201141
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
2/23
Supplementary Materials for MS# 12-01141.R6 Urologists Use of Intensity Modulated Radiation
Therapy for Prostate Cancer
Author: Jean M. Mitchell, Ph.D., Professor of Public Policy, Georgetown University
Table of Contents
1) Sample Selection Criteria Submitted to the Center for Medicare and Medicaid Services2) SAS Program Used to Extract Sample of Men with Newly Diagnosed Prostate Cancer3) SAS Program to Construct Variables Used in IMRT Analysis4) Specification of the Empirical Model5) Table S1: Linear Probability and Logistic Regression Difference-in-Differences Estimates
Predicting Receipt of IMRT Treatments among Medicare Fee-for-Service Beneficiaries with
Newly Diagnosed, Non-metastatic Prostate Cancer
6) Analysis of Time-to-Treat by Self-referral Status7) Figure S1: Frequency of Use of IMRT among Men Age 65-79 with Newly Diagnosed Prostate
Cancer-- Private Practice Self-referring Urologists versus Private Practice Non Self-referring
Urologists
8) Figure S2: Frequency of Use of IMRT among Men Age 80 Plus with Newly Diagnosed ProstateCancer--Private Practice Self-referring Urologists versus Private Practice Non Self-referring
Urologists
9) Figure S3: Frequency of Use of IMRT among Men Age 65-79 with Newly Diagnosed ProstateCancer--Private Practice Self-referring Urologists versus National Comprehensive Cancer
Network Non Self-referring Urologists
10)Figure S4: Frequency of Use of IMRT among Men Age 80 Plus with Newly Diagnosed ProstateCancer--Private Practice Self-referring Urologists versus National Comprehensive Cancer
Network Non Self-referring Urologists
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
3/23
Sample Selection Criteria Submitted to the Center for Medicare and Medicaid Services
The Center for Medicare and Medicaid Services algorithm to identify beneficiaries with prostate
cancer is available on the Chronic Conditions Warehouse website
(ww.ccwdata.org/web/guest/conditions-categories). Prostate cancer is identified by at least 1 inpatient
or two carrier or hospital outpatient claims with ICD-9 diagnosis codes 185 or 233.4.
My data request to CMS stipulated using the Chronic Conditions Warehouse algorithm to extract
Medicare beneficiaries with prostate cancer who were continuously enrolled in fee-for-service during
the time period 2005-2010. Only beneficiaries who resided in 26 designated states were selected. We
attempted to identify newly diagnosed prostate cancer cases in each year by a date variable that
identifies the first occurrence of prostate cancerthe variable CANCER_PROSTATE_EVER.
The data came from 17 states where the 37 self-referring practices identified by the Wall Street
Journal were located. We also requested data for some nearby states where there were no known self-
referring practices. These states include: Connecticut, Georgia, Massachusetts, Michigan, Minnesota,
North Dakota, Tennessee, Utah and Washington. In the process of working with the CMS vendor to
revise the parameters of the original data request to include additional states, Ohio was inadvertently
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
4/23
SAS Program to Extract Sample of Men with Newly Diagnosed Prostate Cancer
We used the SAS program presented below to extract men with newly diagnosed prostate
cancer from the initial data extract obtained. Men with metastatic prostate cancer were excluded.
These cases were identified by ICD-9 codes reported as secondary diagnosis codes on the claims. These
codes are: 198.5 (secondary neoplasm of bone and bone marrow) and 196 (secondary and unspecified
malignant neoplasm of lymph nodes); ICD-9 code 196 has 8 sub codes which describe location.
PROGRAM CODE
%LET GROUP=;
%LET PRED=;
%LET POSTD=;
%LET GRPTAX=;
%LET GRPUPIN=;
%LET GRPNPI=;
%MACRO PYR(YR);
*** check all claims for IDs from group of interest ***;
DATA PRERADGFL_&YR (KEEP=BENE_ID GROUP GROUP_: PRE POST);
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
5/23
RUN;
*** capture all claims for bene that had claim with group of interest - do per year ***;
PROC SORT NODUPKEY DATA=PRERADGFL_&YR;
BY BENE_ID GROUP;
RUN;
DATA PRERADGFL2_&YR;
MERGE PRERADGFL_&YR (IN=A)
INSASG.CMSRAD_&YR (IN=B);
BY BENE_ID;
IF A;
RUN;
%MEND PYR;
%PYR(05);
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
6/23
PRERADGFL2_06
PRERADGFL2_07
PRERADGFL2_08
PRERADGFL2_09
PRERADGFL2_10;
IF GROUP="&GROUP";
RUN;
PROC SORT DATA=PRERAD&GROUP._ALLYR OUT=INSASRAD.PRERAD&GROUP._ALLYR;
BY BENE_ID CLM_THRU_DT;
RUN;
%MEND GRP;
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
7/23
SAS Program to Construct Variables Used in IMRT Analysis
DATA EPISODEBENEPRE_&GROUP (KEEP=BENE_ID BIOPWCANCDATE BIOPSYDATERENAME=(BIOPWCANCDATE=NEWYEAR));
SET INSASRAD.PRERAD&GROUP._ALLYR;
BY BENE_ID CLM_THRU_DT;
RETAIN BIOPWCANCDATE BIOPSYDATE BIOPWCANCF;
IF FIRST.BENE_ID THEN DO;
BIOPWCANCF=0;
BIOPWCANCDATE=.; BIOPSYDATE=.;
END;
*** flag claims with group ***;
IF LEFT(TRIM(TAX_NUM)) IN (&GRPTAX)
OR LEFT(TRIM(PRF_PHYSN_UPIN)) IN (&GRPUPIN)
OR LEFT(TRIM(PRF_PHYSN_NPI)) IN (&GRPNPI) THEN GROUPCLAIM=1;
*** flag claims for prostate cancer diag (including in situ) ***;
ARRAY DIAG(*) $ ICD9_DGNS_CD1-ICD9_DGNS_CD8;
DO I 1 TO DIM(DIAG)
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
8/23
IF LAST.BENE_ID THEN OUTPUT;
RUN;
DATA EPISODEBENEPRE2_&GROUP (RENAME=(PRE=PREDATE POST=POSTDATE));
MERGE EPISODEBENEPRE_&GROUP (IN=A)
INSASRAD.PRERAD&GROUP._ALLYR (IN=B);
BY BENE_ID;
*** 6 month episode ***;
IF A AND B AND ((NEWYEAR-41) LE CLM_THRU_DT LE (NEWYEAR+183));
RUN;
DATA EPISODEBENE_&GROUP (DROP=I J K)
EPISODEBENE3_&GROUP (DROP=I J K)
EPISODEALL_&GROUP (DROP=I J K);
SET EPISODEBENEPRE2_&GROUP;
BY BENE_ID CLM_THRU_DT;
RETAIN &GROUP.COUNT FIRST&GROUP.DATE LAST&GROUP.DATE &GROUP.OFFVISF
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
9/23
IF FIRST.BENE_ID THEN DO;
ARRAY INITZ(*) TREATAGE &GROUP.COUNT &GROUP.OFFVISF PROSTATEF BIOPWCANCF&GROUP.CANCERF CANCERONBIOPF IMRTPF IMRTDF &GROUP.IMRTPF &GROUP.IMRTDF
PROSTATECTOMYF &GROUP.PROSTATECTOMYF BRACHYF &GROUP.BRACHYF
HORMONEF &GROUP.HORMONEF CRYOF &GROUP.CRYOF RADIOF &GROUP.RADIOF TRANSF
&GROUP.TRANSF IMRTPC IMRTDC &GROUP.IMRTPC &GROUP.IMRTDC &GROUP.DAYS CANCERPROC
NOT_&GROUP.IMRTDF NOT_&GROUP.IMRTDC;
DO J=1 TO DIM(INITZ);
INITZ(J)=0;
END;
ARRAY INITM(*) FIRST&GROUP.DATE LAST&GROUP.DATE CDATE FIRST&GROUP.CDATE
BIOPWCANCDATE BIOPSYDATE CANCERONBIOPDATE &GROUP.BIOPSYDATE FIRSTIMRTPDATE
FIRSTIMRTDDATE FIRST&GROUP.IMRTDATE TREATDATE
&GROUP.DATE;
DO K=1 TO DIM(INITM);
INITM(K)=.;
END;
END;
*** fl l i if id i i h f i l fi d f l i i h f l i i h
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
10/23
*** flag claims for prostate cancer diag (including in situ) ***;
ARRAY DIAG(*) $ ICD9_DGNS_CD1-ICD9_DGNS_CD8;
DO I=1 TO DIM(DIAG);
IF DIAG(I) IN ("185","2334") THEN DO;
*** flag claim as prostate cancer, retain flag for bene with prostate cancer, note date of first diagnosis
***;
PROSTATE=1; PROSTATEF=1; IF CDATE=. THEN DO; CDATE=CLM_THRU_DT; END;
*** flag bene for having a cancer diagnosis on a claim by a group dr ***;
IF &GROUP.CLAIM=1 THEN DO; &GROUP.CANCERF=1; IF FIRST&GROUP.CDATE=. THEN
FIRST&GROUP.CDATE=CLM_THRU_DT; END;
IF (CLM_THRU_DT-30) LE BIOPSYDATE THEN DO; BIOPWCANCF=1; IF BIOPWCANCDATE=.
THEN BIOPWCANCDATE=CLM_THRU_DT; END;
IF CLM_THRU_DT=BIOPWCANCDATE THEN CANCERPROC=1;
END;
END;
*** flag claim and bene for having office visit with dr in group ***;
IF SUBSTR(HCPCS_CD,1,3)='992' AND &GROUP.CLAIM=1 THEN DO;
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
11/23
IF &GROUP.CLAIM=1 THEN &GROUP.BIOPSYDATE=CLM_THRU_DT;
END;
*** flag treatments - from group and from anyone ***;
IF HCPCS_CD="77301" THEN DO;
IMRTP=1; IMRTPF=1; IMRTPC+SUM(REV_CNTR_UNIT_CNT,LINE_SRVC_CNT);
IF FIRSTIMRTPDATE=. THEN FIRSTIMRTPDATE=CLM_THRU_DT;
IF &GROUP.CLAIM=1 THEN DO; IF FIRST&GROUP.IMRTDATE=. THEN
FIRST&GROUP.IMRTDATE=CLM_THRU_DT; &GROUP.IMRTP=1; &GROUP.IMRTPF=1;
&GROUP.IMRTPC+SUM(REV_CNTR_UNIT_CNT,LINE_SRVC_CNT); END;
END;
IF HCPCS_CD="77418" THEN DO;
IMRTD=1; IMRTDF=1; IMRTDC+SUM(REV_CNTR_UNIT_CNT,LINE_SRVC_CNT);
IF FIRSTIMRTDDATE=. THEN FIRSTIMRTDDATE=CLM_THRU_DT;
IF &GROUP.CLAIM=1 THEN DO; IF FIRST&GROUP.IMRTDATE=. THEN
FIRST&GROUP.IMRTDATE=CLM_THRU_DT; &GROUP.IMRTD=1; &GROUP.IMRTDF=1;
&GROUP.IMRTDC+SUM(REV_CNTR_UNIT_CNT,LINE_SRVC_CNT); END;
IF &GROUP.CLAIM NE 1 THEN DO; NOT_&GROUP.IMRTD=1; NOT_&GROUP.IMRTDF=1;
NOT_&GROUP.IMRTDC+SUM(REV_CNTR_UNIT_CNT,LINE_SRVC_CNT); END;
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
12/23
IF HCPCS_CD IN ("77435","G0339","G0340") THEN DO; RADIO=1; RADIOF=1; IF &GROUP.CLAIM=1
THEN &GROUP.RADIOF=1; END;
IF HCPCS_CD IN ("53850","53852","53853", "52601") THEN DO; TRANS=1; TRANSF=1; IF
&GROUP.CLAIM=1 THEN &GROUP.TRANSF=1; END;
*** note first date of treatment ***;
IF TREATDATE=. AND (PROSTATECTOMY=1 OR BRACHY=1 OR IMRTD=1) THEN DO;
TREATDATE=CLM_THRU_DT;
TREATAGE=BENE_AGE_AT_END_REF_YR;
END;
LABEL PROSTATE="claim has malignant neoplasm/in situ of prostate"
PROSTATEF="bene has malignant neoplasm/in situ of prostate"
SECONDF="bene has a secondary treatment - prostatectomy, brachy"
TERTIARYF="bene has a tertiary treatment - cryo, radio, trans"
IMRTDF="bene had IMRT delivery (77418)"
IMRTPF="bene had IMRT planning (77301)"
BIOPWCANCF="bene has a biopsy and a cancer diagnosis w/in 30 days"
CANCERONBIOPF="bene has a cancer diagnosis on a biopsy claim"
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
13/23
IF LAST&GROUP.DATEMDY(6,30,2010) THEN NEWDIAG=0;
IF &GROUP.PROSTATECTOMYF=1 OR &GROUP.BRACHYF=1 THEN &GROUP.SECONDF=1;
IF &GROUP.CRYOF=1 OR &GROUP.RADIOF=1 OR &GROUP.TRANSF=1 THEN &GROUP.TERTIARYF=1;
IF &GROUP.IMRTDF=1 AND SECONDF NE 1 THEN &GROUP.IMRTDONLY=1;
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
14/23
*** 6 month requirement for pre period ***;
IF PRE=1 AND NEWDIAG=1 AND BIOPWCANCDATE>(PREDATE-183) THEN NEWDIAG=0;
IF FIRSTIMRTPDATE NE . AND FIRSTIMRTDDATE NE . THEN IMRTP2D=FIRSTIMRTDDATE-
FIRSTIMRTPDATE;
*** do not include benes with
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
15/23
Specification of the Empirical Model
The dependent variable receipt of IMRT treatments equals 1 if: 1) the beneficiary was seen by a
non self-referring urologist in either the preownership or ownership periods and he received IMRT
treatments; or 2) the beneficiary was seen by a self-referring urologist in the preownership period and
he received IMRT treatments; or 3) the beneficiary was seen by a self-referring urologist in the
ownership period and he received IMRT treatments performed and billed by the self-referring urology
group. For all other observations the dependent variable equals zero. This includes beneficiaries seen by
a self-referring urologist during the ownership period that underwent IMRT treatments performed and
billed by a non self-referring provider (about 6% of the primary sample). Although these beneficiaries
received IMRT treatments, assigning a value of 1 to these cases would bias upward the coefficient on
the self-referral variable.
The unadjusted analyses only control for: 1) whether the case was treated in the preownership
or ownership period, 2) self-referral status and 3) whether the patient was treated by a self-referring
urologist after acquiring ownership. The unadjusted analyses do not control for any other confounding
factors. Each matched pair has the same preownership and ownership period.
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
16/23
rapidly adopted during the time period of study, despite uncertainty regarding its relative effectiveness.2
Indicator variables identifying the 70 urology groups that comprise the primary sample were included to
control for variations in physician practices patterns that are likely to exist but are unrelated to self-
referral status.
References
1. Elixhauser, A, Steiner, C, Harris, DR and Coffey RM. Comorbidity Measures for Use with
Administrative Data. Medical Care. 1998; 36(1): 8-27.
2 . Jacobs BL, Zhong Y, Skolarus, TA, Hollenbeck, BK. Growth of High-Cost Intensity Modulated
Radiation Therapy for Prostate Cancer Raises Concerns about Overuse.
Health Affairs, 2012; 31(4): 750-759.
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
17/23
Table S1. Linear Probability and Logistic Regression Difference-in-Differences Estimates
Predicting Receipt of IMRT Treatments among Fee-for-Service Medicare Beneficiaries with
Newly Diagnosed Non-metastatic Prostate Cancera
Private Practice Self-referring Private Practice Self-referring
Urologists vs. Private Practice Urologists vs. NCCN
Non Self-referring Urologistsc
Non Self-referring Urologistsd
Beneficiary Treated by Self-
referring Urologist during
Ownership Period (n= 38,765)
Beneficiary Treated by Self-
referring Urologist during
Ownership Period (n=6,773)Marginal EffectLinearProbability Model
16.4% points
(p
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
18/23
Analysis of Time-to-Treat by Self-referral Status
Self-referring urologists contend that the vertically integrated urology-radiation oncology
practice reduces time-to-treat, that is, time from date of cancer diagnosis to initiation of definitive
treatment. If so then one would expect to find that men treated by self-referring urologists will
experience a reduction in time-to-treat compared to men who obtained care from non self-referring
urologists. Results reported below show this is not the case. After controlling for type of definitive
treatment received (brachytherapy, IMRT only or prostatectomy) and other confounding factors, time-
to-treat does not vary by self-referral status.
Table S2. Length of Time from Date of Prostate Cancer Diagnosis to Date of Receipt of Definitive
Treatment (Brachytherapy, Prostatectomy, IMRT)
Sample Difference-in-Differences
(Self-referral) Effect
(Unadjusted)
Difference-in-Differences
(Self-referral) Effect
(Adjusted)b
Private Practice Self-referring Urologists
Versus Private Practice Non Self-referring
Urologists
-3.0
(p
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
19/23
In addition, we estimated a regression where the dependent variable was length of time in days from
date of diagnosis until receipt of definitive treatment controlling for treatment by a self-referring
urologist in the ownership period, urology group fixed effects, type of definitive treatment
(brachytherapy, IMRT only or prostatectomy), age, year of cancer diagnosis and comorbid illnesses. The
coefficient on the self-referral variable was 1.29 (p = 0.12) and was not statistically significant. Thus, the
regression-adjusted results show there was no difference in length of time from date of cancer diagnosis
to receipt of definitive treatment associated with self-referral.
Private Practice Self-referring Urologists versus National Comprehensive Cancer Network
Non Self-referring Urologists
Difference-in-difference results from time-to-treat comparisons of men treated by self-
referring urologists and their non self-referring counterparts employed by cancer centers are reported in
row 2 of Table S2. The unadjusted difference-in-differences estimator or self-referral effect was a
decline in time-to-treat of 6.4 days (p
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
20/23
19
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
21/23
20
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
22/23
21
7/27/2019 Supplement to the Urologists-IMRT study from the New England Journal of Medicine
23/23
22